Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines. The company has developed numerous innovative treatments and vaccines for both human and animal health. Recently, Merck released its fourth-quarter and full-year 2024 earnings. While the company exceeded revenue and earnings expectations, its stock dropped 9% due to a cautious 2025 outlook that disappointed investors. So far this year, Merck shares have declined 12.3%, compared to the S&P 500 Index’s ($SPX) gain of 3.1%. However, analysts project potential upside of 92% in 2025, according to the Street-high estimate.
Investors should also note that Merck pays a dividend yielding 3.71%, more than twice the healthcare sector average.
